Drug Topics September 20, 2024
Check out important updates from the FDA for the week of September 16.
FDA Clears First 1-Year CGM for Diabetes
The FDA has given clearance to the continuous glucose monitor (CGM) Eversense 365 for adult patients with type 1 and type 2 diabetes, Senseonics and Ascensia Diabetes Care announced in a release. Ascensia said that it anticipates a launch of the product to occur in the United States in the fourth quarter of this year.
The Eversense 365 is the world’s first long-term CGM that provides patients with 1 year of use. The fully-implantable device allows for minimal life disruption compared to short-term CGMs, which typically last around 10 to 14 days. The CGMs 12-month survivability also reduces data interruptions...
Today's Sponsors
Today's Sponsor